 Litanoprost, LTP, is a prostaglandin F2-alpha analogue used to treat glaucoma. It can be administered via eye drops or other routes such as intraconjunctival, intravitrial, subconjunctival, and subcutaneous injection. A new drug delivery system has been developed using a polylactic cobalicolic acid, based polymer matrix with shape memory and electron beam irradiation. This system allows for sustained release of LTP over a period of 113 days, with a longer second release phase and no burst effect. Additionally, the drug delivery system can reduce the number of drops needed at the beginning of treatment, as well as decrease the amount of time required for administration. This article was authored by Alexander Bereka, Jakob Rech, Henrik Jainzek, and others.